MX2023003009A - Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer. - Google Patents
Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2023003009A MX2023003009A MX2023003009A MX2023003009A MX2023003009A MX 2023003009 A MX2023003009 A MX 2023003009A MX 2023003009 A MX2023003009 A MX 2023003009A MX 2023003009 A MX2023003009 A MX 2023003009A MX 2023003009 A MX2023003009 A MX 2023003009A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid
- disease
- beta
- alzheimer
- peptide
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000007082 Aβ accumulation Effects 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079806P | 2020-09-17 | 2020-09-17 | |
| PCT/US2021/033180 WO2022060424A1 (en) | 2020-09-17 | 2021-05-19 | β-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003009A true MX2023003009A (es) | 2023-04-10 |
Family
ID=80776325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003009A MX2023003009A (es) | 2020-09-17 | 2021-05-19 | Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230364210A1 (https=) |
| EP (1) | EP4213942A4 (https=) |
| JP (1) | JP2023541669A (https=) |
| KR (1) | KR20230087495A (https=) |
| CN (1) | CN116724046A (https=) |
| AR (1) | AR122127A1 (https=) |
| AU (1) | AU2021345451A1 (https=) |
| CA (1) | CA3192383A1 (https=) |
| IL (1) | IL301223A (https=) |
| MX (1) | MX2023003009A (https=) |
| TW (1) | TW202212348A (https=) |
| WO (1) | WO2022060424A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| EP4661891A2 (en) * | 2023-02-06 | 2025-12-17 | Creative Bio-Peptides Inc. | Peptides for treating neurological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840838A (en) * | 1996-02-29 | 1998-11-24 | University Of Kentucky Research Foundation | Process for enhancing the activity of amyloid β peptides |
| US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| US12304935B2 (en) * | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| BR112022023366A2 (pt) * | 2020-05-19 | 2023-05-02 | Othair Prothena Ltd | Vacina com múltiplos epítopos para o tratamento de mal de alzheimer |
-
2021
- 2021-05-19 US US18/245,523 patent/US20230364210A1/en active Pending
- 2021-05-19 TW TW110118154A patent/TW202212348A/zh unknown
- 2021-05-19 AR ARP210101370A patent/AR122127A1/es unknown
- 2021-05-19 CA CA3192383A patent/CA3192383A1/en active Pending
- 2021-05-19 JP JP2023517697A patent/JP2023541669A/ja active Pending
- 2021-05-19 AU AU2021345451A patent/AU2021345451A1/en active Pending
- 2021-05-19 EP EP21869919.7A patent/EP4213942A4/en active Pending
- 2021-05-19 CN CN202180063988.4A patent/CN116724046A/zh active Pending
- 2021-05-19 MX MX2023003009A patent/MX2023003009A/es unknown
- 2021-05-19 WO PCT/US2021/033180 patent/WO2022060424A1/en not_active Ceased
- 2021-05-19 IL IL301223A patent/IL301223A/en unknown
- 2021-05-19 KR KR1020237012808A patent/KR20230087495A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021345451A1 (en) | 2023-04-13 |
| US20230364210A1 (en) | 2023-11-16 |
| IL301223A (en) | 2023-05-01 |
| EP4213942A4 (en) | 2025-01-08 |
| TW202212348A (zh) | 2022-04-01 |
| EP4213942A1 (en) | 2023-07-26 |
| JP2023541669A (ja) | 2023-10-03 |
| WO2022060424A1 (en) | 2022-03-24 |
| KR20230087495A (ko) | 2023-06-16 |
| CN116724046A (zh) | 2023-09-08 |
| AR122127A1 (es) | 2022-08-17 |
| CA3192383A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003009A (es) | Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer. | |
| PH12022553234A1 (en) | Multi-epitope vaccine for the treatment of alzheimer`s disease | |
| MX2023003008A (es) | Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. | |
| MX2023001503A (es) | Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer. | |
| MX2023001501A (es) | Vacuna tau para tratamiento de enfermedad de alzheimer. | |
| NZ589807A (en) | Method for preventing and treating neurodegenerative diseases using a grape seed extract having less than 12% by weight galloylated proanthocyanidins | |
| ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
| MX384227B (es) | Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis. | |
| BR0011103A (pt) | Composição farmacêutica, e, métodos para prevenção ou tratamento de um distúrbio caracterizado por deposição amilóide em um sujeito mamìfero, para determinar o prognóstico de um paciente que está sendo submetido a tratamento de um distúrbio amilóide e para prevenção ou tratamento de uma doença caracterizada por um depósito amilóide em um paciente | |
| MX2023003007A (es) | Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
| EA201000441A1 (ru) | Водные офтальмологические препараты | |
| Gonsette et al. | Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| JP2016539911A5 (https=) | ||
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| CN105612179B (zh) | 单克隆olfml-3抗体及其用途 | |
| CA3111512A1 (en) | Methods and compositions for inducing neural plasticity | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| Epifanova et al. | HP-09-006 First results of platelet-rich plasma and low intensity extracorporeal shockwave combined therapy for erectile dysfunction | |
| MX2022012252A (es) | Metodos para tratar la enfermedad de alzheimer. |